Bridging the gap between islet allotransplantation and regulatory reform
Drug Discovery World
SEPTEMBER 26, 2024
In fact, between 2016 and 2019 1 , only 11 patients in the US underwent this procedure, and all were part of clinical trials. The root of this issue lies in the outdated regulatory framework that classifies islet cells as drugs rather than organs or tissue.
147 
Let's personalize your content